Clinical trials: Neoantigens
A Single Patient Will be Treated With Individual Patient TCR-Transduced PBL
A single patient will be treated with Individual Patient TCR-Transduced PBL
- Trial name
- NCT04194190
- Testing
- Individual Patient TCR-Transduced PBL
- Sponsor
- National Institutes of Health Clinical Center (CC)
Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
Single Patient Expanded Access
- Trial name
- NCT04135092
- Testing
- Individual Patient TCR Transduced PBL, Cyclophosphamide, Fludarabine
- Sponsor
- National Institutes of Health Clinical Center (CC)
Malignant Epithelial Neoplasms
Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
This is a phase I/Ib study of adoptively transferred T-cell receptor gene-engineered T cells (TCR-T) targeting tumor-specific antigens, with in vivo CD40 activation and PD-1 blockade, for patients with incurable cancers.
- Trial name
- NCT04520711
- Testing
- TCR-transduced T cells, CDX-1140, Pembrolizumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Providence Health & Services
Esophageal Cancer, Neoantigen
Computational Prediction and Experimental Validation of Esophageal Cancer Associated Neoantigens
This study is to develop computational pipelines and experimental validation assays for improving the identification of neoantigens from patients with esophageal cancer.
- Trial name
- NCT05498168
- Testing
- ratio of predicted neoantigens
- Where
- Vietnam
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University Medical Center Ho Chi Minh City (UMC)
Colonic Neoplasms, Colorectal Neoplasms
Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
The primary objective is to assess and characterize the antitumor activity and safety and tolerability of adjuvant treatment with an individualized neoantigen vaccine called GRT-C901/GRT-R902 (chimpanzee adenovirus [ChAd] and…
- Trial name
- NCT05456165
- Testing
- GRT-C901, GRT-R902, Atezolizumab
- Where
- 3 sites in United States
- Sponsor
- Gritstone bio, Inc.
Malignant Epithelial Neoplasms
Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)
This is a phase I/Ib study of adoptively transferred T-cell receptor gene-engineered T cells (TCR-T) targeting tumor-specific antigens, with in vivo CD40 activation and PD-1 blockade, for patients with incurable cancers.
- Trial name
- NCT05349890
- Testing
- TCR-transduced T cells, CDX-1140, Pembrolizumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Providence Health & Services
Gastric Cancer, Neoantigens
Computational Prediction and Experimental Validation of Gastric Cancer Associated Neoantigens
This study is to develop methods for identification of neoantigens from patients with gastric cancer.
- Trial name
- NCT05498194
- Testing
- ratio of predicted neoantigens
- Where
- Vietnam
- Volunteers
- 50 people
- Sponsor
- University Medical Center Ho Chi Minh City (UMC)
Primary/Relapsed Acute Lymphoblastic Leukemia (ALL) of Childhood, Adolescents and Young Adults
Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL
The aim of this clinical study is to evaluate the feasibility and safety of an individualized peptide vaccination approach in patients with acute lymphoblastic leukemia (ALL).
- Trial name
- NCT03559413
- Testing
- Individual peptide vaccination with adjuvant GM-CSF and Imiquimod
- Where
- 5 sites in Germany
- Volunteers
- 30 people
- Sponsor
- University Children's Hospital Tuebingen
Endometrial Carcinoma, Endometrial Carcinoma Stage III
GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer
GYNORYLAQ-VLINIVAL is an Early Phase I, non-randomized, single-arm, open-label clinical trial enrolling 40 patients with high-risk or recurrent endometrial carcinoma.
- Trial name
- GYNORYLAQ™ (NCT07316361)
- Testing
- • Biological: GYNORYLAQ-TM Personalized Neoantigenic Peptide Vaccine
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- Biogenea Pharmaceuticals Ltd.